Importancia del diagnóstico molecular en el GIST
El diagnóstico molecular en GIST impulsa tratamientos personalizados y más eficaces, dando forma al futuro de la precisión en la medicina.
Impact of Molecular Diagnosis in GIST
Molecular diagnosis in GIST drives personalized, more effective treatments, shaping the future of precision medicine.
New Life Raft Group Paper Published
The LRG publishes, "Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry" Cancer Investigation ,Vol. 41, 2023. Issue 5 [...]
European Patient Cancer Coalition Publishes Patient Guide for Cancer Biomarkers
European Patient Cancer Coalition published Patient Guide for Cancer Biomarkers in January 2023.
Our Latest Publication Focused on Mutational Testing
The LRG published "Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of Life Raft Group members" in BMC Gastroenterology, November 2022.
The Importance of Biomarker Testing
The Life Raft Group partnered with Dr. Michael Wagner of the University of Washington to present “The Importance of Biomarker Testing” to GIST patients and caregivers on August 12th, 2022.
Did You Know? Tissue Testing FREE for GIST Patients!
The Life Raft Group is currently conducting a tissue testing initiative for GIST patients to receive FREE Next-Generation Sequencing (NGS) Testing!
The Value of Biomarker Testing: Case Studies Across Multiple Institutions
In this webinar, there were case study presentations from three top sarcoma institutions that demonstrate the value of biomarker testing. A Question & Answer session followed the presentations.
Tissue Testing Project
The Life Raft Group (LRG) is providing you with this information to let you know that comprehensive genomic profiling, also known as biomarker testing or molecular testing, is a crucial step in understanding the genomic factors that play a role in a GIST diagnosis. Bayer Pharmaceuticals, in partnership with The Life Raft Group (LRG), has extended a research collaboration to broaden access to comprehensive genomic testing (CGT) for Gastrointestinal Stromal Tumor (GIST) patients.
The Importance of Biomarker Testing for the Effective Treatment of GIST Patients – LRG Science
This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient's journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.